HA, DAL, AIRM were Most Active Air Line Stocks Gainers : by Penny Stock Pick Alert
|
| Posted
:
Sat, 07 Nov 2009 20:01:35 GMT |
| Author
:
Mailwire |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
(EMAILWIRE.COM, November 07, 2009 ) Dallas, TX - Hawaiian Holdings, Inc. (NASDAQ:HA) is one of the most active gainers in today`s trading session as it surges over 2.64% to $7.00 after crude oil fell 2% today. The Stock hit an intraday high and an intraday low of $7.11 and $6.96 respectively. In the last six months the stock went up over 26%. Hawaiian Holdings, Inc. is a holding company whose primary asset is the sole ownership of all issued and outstanding shares of common stock of Hawaiian Airlines, Inc.
Delta Air Lines, Inc. (NYSE:DAL) increases 6.28% to $7.79 on a volume of 9.31 million shares after Crude-oil futures were down 2% to about $78 a barrel in electronic trading. The Stock hit an intraday high and an intraday low of $7.95 and $7.29 respectively. In the last six months the stock went up over 6%. Delta Air Lines, Inc. is an airline service provider. The Company from its hubs in Atlanta, Cincinnati, Detroit, Memphis, Minneapolis-St. Paul, New York-JFK, Salt Lake City, Paris-Charles de Gaulle, Amsterdam and Tokyo-Narita, Delta, its Northwest subsidiary and Delta Connection carriers, offers service to 370 destinations in 66 countries and serve more than 170 million passengers each year.
Air Methods Corporation (NASDAQ:AIRM) is one of the most active gainers in today`s trading session as it surges over 5.69% to $34.55 after crude oil fell over 2% today. The company yesterday reported results for the quarter ended September 30, 2009. Revenue increased 3% to $137.6 million from $133.8 million in the year-ago quarter. For the nine-month period, revenue increased 3% to $390.4 million, up from $379.9 million in the prior-year nine-month period.
ABOUT www.PennyStockPickAlert.com
Penny Stock Pick Alerts by PennyStockPickAlert.com. If you are planning to invest into Stock Market then you must subscribe to Free Stock Newsletter and Alerts. We are a leading stock web site that provides free stock alerts on hot penny stocks that are poised to make big gains. We also tracks small cap penny stocks that could be on the brink of a massive breakout.
PennyStockPickAlert.com
Robert Wilson
214 556 6798
info@pennystockpickalert.com
|
|
|
|
|
|
|
Related
News
Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
NEW ORLEANS, Dec. 6 -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refrac...
Gloucester Pharmaceuticals Presents ISTODAX® Data Demonstrating Clinical Benefit in Patients with CTCL Including Blood Involvement at ASH Annual Meeting
CAMBRIDGE, Mass. -
Gloucester Pharmaceuticals announced today the presentation of positive
data from an analysis of ISTODAX® (romidepsin) in a subset of
patients from Gloucester’s registration study in cutaneous T-cell
lymphoma (CTCL) at the 51st American Soci
Researchers Report Clinical Association Between Type II PNH Cells and Thrombocytopenia
CHESHIRE, Conn. -
Alexion
Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced pre
Hip-Hop Star Nelly Hosts His 4th Annual Black and White Ball
ST. LOUIS, Dec. 6 /PRNewswire/ -- The Black and White Ball, St. Louis' premier celebrity gala event, will take place on December 6th at the Chase Park Plaza hotel. Hosted by rapper/actor/entrepreneur Nelly, the annual black-tie holiday-season celebration is a highlight of the city's...
RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
RIDGEFIELD, Conn., Dec. 6 /PRNewswire/ -- Boehringer Ingelheim today announced results from the RE-COVER(TM) study investigating dabigatran etexilate (150 mg BID), a direct thrombin inhibitor (DTI),(2) compared to dose-adjusted warfarin in patients with acute VTE. Results o...
Phase III Study of Rivaroxaban Shows That Extending Anticoagulant Treatment by Six or 12 Months Significantly Reduced Risk of Second Symptomatic VTE
NEW ORLEANS -
Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
(J&JPRD), announced today that results from the Phase III
EINSTEIN-Extension (EXT) clinical trial of the novel oral anticoagulant
rivaroxaban showed a significant reduction in the risk of recurrent
Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages
NEW ORLEANS, Dec. 6 /PRNewswire-USNewswire/ -- Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a p...
|
|
|
|
|
|
|
|
|
